All Relations between Epilepsy and cannabis

Reference Sentence Publish Date Extraction Date Species
Carol J Milligan, Lyndsey L Anderson, Michael T Bowen, Samuel D Banister, Iain S McGregor, Jonathon C Arnold, Steven Petro. A nutraceutical product, extracted from Cannabis sativa, modulates voltage-gated sodium channel function. Journal of cannabis research vol 4 issue 1 2022 35689251 purified cannabidiol (cbd), a non-psychoactive phytocannabinoid, has gained regulatory approval to treat intractable childhood epilepsies. 2022-06-10 2022-06-13 Not clear
Orrin Devinsky, Angelica Marmanillo, Theresa Hamlin, Philip Wilken, Daniel Ryan, Conor Anderson, Daniel Friedman, George Tod. Observational study of medical marijuana as a treatment for treatment-resistant epilepsies. Annals of clinical and translational neurology vol issue 2022 35267245 observational study of medical marijuana as a treatment for treatment-resistant epilepsies. 2022-03-10 2022-04-14 Not clear
Sandip Patel, Reid Grinspoon, Bradley Fleming, Lauren A Skirvin, Christina Wade, Emma Wolper, Patricia L Bruno, Elizabeth A Thiel. The long-term efficacy of cannabidiol in the treatment of refractory epilepsy. Epilepsia vol 62 issue 7 2021 34050682 cannabidiol (cbd) has been shown to reduce seizures among patients with refractory epilepsies of various etiologies in recent clinical trials and an expanded access program (eap). 2021-10-15 2022-01-13 Not clear
Joseph L Damstra-Oddy, Eleanor C Warren, Christopher J Perry, Yann Desfoug\\xc3\\xa8res, John-Mark K Fitzpatrick, Judith Schaf, Lisa Costelloe, William Hind, Eric J Downer, Adolfo Saiardi, Robin S B William. Phytocannabinoid-dependent mTORC1 regulation is dependent upon inositol polyphosphate multikinase activity. British journal of pharmacology vol 178 issue 5 2021 33347604 cannabidiol (cbd) has been shown to differentially regulate the mechanistic target of rapamycin complex 1 (mtorc1) in preclinical models of disease, where it reduces activity in models of epilepsies and cancer and increases it in models of multiple sclerosis (ms) and psychosis. 2021-07-05 2022-01-13 Not clear
Claire M Williams, Gary J Stephen. Development of cannabidiol as a treatment for severe childhood epilepsies. British journal of pharmacology vol 177 issue 24 2021 32986848 development of cannabidiol as a treatment for severe childhood epilepsies. 2021-06-21 2022-01-13 Not clear
Andrew J Roebuck, Quentin Greba, Anna-Maria Smolyakova, Mariam Alaverdashvili, Wendie N Marks, Sumanta Garai, Samantha L Baglot, Gavin Petrie, Stuart M Cain, Terrance P Snutch, Ganesh A Thakur, Matthew N Hill, John G Howland, Robert B Laprairi. Positive allosteric modulation of type 1 cannabinoid receptors reduces spike-and-wave discharges in Genetic Absence Epilepsy Rats from Strasbourg. Neuropharmacology vol 190 issue 2021 33845076 certain cannabinoids, such as cannabidiol (cbd), have shown promise in the treatment of pediatric epilepsies. 2021-06-09 2022-01-13 Not clear
Vaishali Satpute Janve, Lyndsey L Anderson, Dilara Bahceci, Nicole A Hawkins, Jennifer A Kearney, Jonathon C Arnol. The Heat Sensing Trpv1 Receptor Is Not a Viable Anticonvulsant Drug Target in the Frontiers in pharmacology vol 12 issue 2021 34079465 the heat sensing trpv1 receptor is not a viable anticonvulsant drug target in the cannabidiol has been approved for the treatment of drug-resistant childhood epilepsies including dravet syndrome (ds). 2021-06-05 2022-01-13 Not clear
Lyndsey L Anderson, Ivan K Low, Iain S McGregor, Jonathon C Arnol. Interactions between cannabidiol and \\xce\\x94 British journal of pharmacology vol 177 issue 18 2021 32608111 interactions between cannabidiol and \xce\x94 extracts from the cannabis plant can dramatically improve the health of children suffering from refractory epilepsies such as dravet syndrome. 2021-05-27 2022-01-13 Not clear
Randi von Wrede, Christoph Helmstaedter, Rainer Surge. Cannabidiol in the Treatment of Epilepsy. Clinical drug investigation vol 41 issue 3 2021 33559102 anecdotal reports addressing the successful seizure treatment of severe epilepsies with cannabidiol (cbd) have increased both public interest and academic research. 2021-05-04 2022-01-13 Not clear
Birgitta Metternich, Kathrin Wagner, Maximilian J Geiger, Martin Hirsch, Andreas Schulze-Bonhage, Kerstin A Klot. Cognitive and behavioral effects of cannabidiol in patients with treatment-resistant epilepsy. Epilepsy & behavior : E&B vol 114 issue Pt A 2021 33246899 therapeutic use of cannabidiol (cbd) in intractable epilepsies has increased considerably over the last ten years. 2021-04-19 2022-01-13 Not clear
Rafael M Bitencourt, Reinaldo N Takahashi, Elisaldo A Carlin. From an Alternative Medicine to a New Treatment for Refractory Epilepsies: Can Cannabidiol Follow the Same Path to Treat Neuropsychiatric Disorders? Frontiers in psychiatry vol 12 issue 2021 33643100 from an alternative medicine to a new treatment for refractory epilepsies: can cannabidiol follow the same path to treat neuropsychiatric disorders? 2021-03-03 2022-01-13 Not clear
Willian Lazarini-Lopes, Raquel A Do Val-da Silva, Rui M P da Silva-J\\xc3\\xbanior, Jo\\xc3\\xa3o P Leite, Norberto Garcia-Cairasc. The anticonvulsant effects of cannabidiol in experimental models of epileptic seizures: From behavior and mechanisms to clinical insights. Neuroscience and biobehavioral reviews vol 111 issue 2021 31954723 in this context, cannabidiol (cbd), a non-psychoactive phytocannabinoid present in cannabis, has been a promising compound for treating epilepsies due to its anticonvulsant properties in animal models and humans, especially in pharmacoresistant patients. 2021-01-05 2022-01-13 Not clear
Umberto Raucci, Nicola Pietrafusa, Maria Chiara Paolino, Giovanni Di Nardo, Maria Pia Villa, Piero Pavone, Gianluca Terrin, Nicola Specchio, Pasquale Striano, Pasquale Paris. Cannabidiol Treatment for Refractory Epilepsies in Pediatrics. Frontiers in pharmacology vol 11 issue 2020 33117180 cannabidiol treatment for refractory epilepsies in pediatrics. 2020-10-30 2022-01-13 Not clear
Gianluca D'Onofrio, Mathieu Kuchenbuch, Caroline Hachon-Le Camus, B\\xc3\\xa9atrice Desnous, V\\xc3\\xa9ronique Staath, Sylvia Napuri, Doroth\\xc3\\xa9e Ville, Jean-Michel Pedespan, Anne L\\xc3\\xa9pine, Claude Cances, Anne de Saint-Martin, Th\\xc3\\xa9o Teng, Nicole Chemaly, Mathieu Milh, Nathalie Villeneuve, Rima Nabbou. Slow Titration of Cannabidiol Add-On in Drug-Resistant Epilepsies Can Improve Safety With Maintained Efficacy in an Open-Label Study. Frontiers in neurology vol 11 issue 2020 32903409 slow titration of cannabidiol add-on in drug-resistant epilepsies can improve safety with maintained efficacy in an open-label study. 2020-09-28 2022-01-13 Not clear
Kelsey Poisson, Matthew Wong, Chon Lee, Maria Roberta Cili. Response to cannabidiol in epilepsy of infancy with migrating focal seizures associated with KCNT1 mutations: An open-label, prospective, interventional study. European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society vol 25 issue 2020 31926846 cannabidiol (cbd) has recently arisen in public interest due to its potential in treatment-resistant epilepsies as demonstrated in randomized controlled trials for dravet syndrome and lennox-gastaut syndrome. 2020-08-17 2022-01-13 Not clear
Linda C Laux, E Martina Bebin, Daniel Checketts, Michael Chez, Robert Flamini, Eric D Marsh, Ian Miller, Kathryn Nichol, Yong Park, Eric Segal, Laurie Seltzer, Jerzy P Szaflarski, Elizabeth A Thiele, Arie Weinstoc. Long-term safety and efficacy of cannabidiol in children and adults with treatment resistant Lennox-Gastaut syndrome or Dravet syndrome: Expanded access program results. Epilepsy research vol 154 issue 2020 31022635 since 2014, patients with severe treatment-resistant epilepsies (tres) have been receiving add-on cannabidiol (cbd) in an ongoing, expanded access program (eap), which closely reflects clinical practice. 2020-07-13 2022-01-13 Not clear
Debopam Samant. Cannabidiol: A Review of Clinical Efficacy and Safety in Epilepsy. Pediatric neurology vol 96 issue 2020 31053391 the us food and drug administration (fda) has approved pharmaceutical-grade cannabidiol oil for two childhood-onset catastrophic epilepsies: dravet syndrome and lennox-gastaut syndrome. 2020-05-01 2022-01-13 Not clear
Kerstin A Klotz, Martin Hirsch, Marcel Heers, Andreas Schulze-Bonhage, Julia Jacob. Effects of cannabidiol on brivaracetam plasma levels. Epilepsia vol 60 issue 7 2020 31211851 the use of cannabidiol (cbd) for treatment of pharmacoresistant epilepsies is increasing. 2020-04-14 2022-01-13 Not clear
Khalid A Jadoon, Garry D Tan, Saoirse E O'Sulliva. A single dose of cannabidiol reduces blood pressure in healthy volunteers in a randomized crossover study. JCI insight vol 2 issue 12 2020 28614793 cannabidiol (cbd) is a nonpsychoactive phytocannabinoid used in multiple sclerosis and intractable epilepsies. 2020-03-09 2022-01-13 Not clear
Nicola Pietrafusa, Alessandro Ferretti, Marina Trivisano, Luca de Palma, Costanza Calabrese, Giusy Carf\\xc3\\xac Pavia, Ilaria Tondo, Simona Cappelletti, Federico Vigevano, Nicola Specchi. Purified Cannabidiol for Treatment of Refractory Epilepsies in Pediatric Patients with Developmental and Epileptic Encephalopathy. Paediatric drugs vol 21 issue 4 2019 31179531 purified cannabidiol for treatment of refractory epilepsies in pediatric patients with developmental and epileptic encephalopathy. 2019-10-30 2022-01-13 Not clear
1   2